Cosmo Pharmaceuticals ROE 2024

Cosmo Pharmaceuticals Aktienanalyse

What does Cosmo Pharmaceuticals do?

Cosmo Pharmaceuticals NV is an international pharmaceutical company based in Dublin, Ireland. The company focuses on developing innovative drugs for various diseases, including gastroenterology, oncology, and infectious diseases. The history of Cosmo Pharmaceuticals dates back to 1997 when it was founded by Dr. Mauro Ajani in Italy. Since then, the company has undergone impressive development and is now listed on the SIX Swiss Exchange. In 2020, the company moved from Italy to Ireland to strengthen its international presence. Cosmo Pharmaceuticals' business model is based on creating patented innovations and technologies in drug development. The company works closely with other companies and research institutions to introduce a wide range of products that benefit both patients and healthcare providers. The main source of income for Cosmo Pharmaceuticals is the licenses they grant for their products, as well as the manufacturing and sale of their own products. Cosmo Pharmaceuticals operates three main business areas: Human, Veterinary, and Proprietary. The Human division specializes in the development of drugs for humans. The company's products are available worldwide, including in the United States, Europe, Japan, and China. In the field of gastroenterology, Cosmo Pharmaceuticals is one of the leading companies on the market and has developed several products to treat gastrointestinal problems and other gastrointestinal diseases. The Veterinary division of Cosmo Pharmaceuticals specializes in the development of animal medicines. The company works with veterinarians and pet owners to bring products to market that help animals stay healthy or recover. Cosmo Pharmaceuticals offers several products tailored to the specific needs of animals, including Ballistol Animal, used for skin and fur care, and Otilonium Bromide, used for digestive disorders in horses. The Proprietary division is the third major business area of Cosmo Pharmaceuticals. This is a segment that manufactures its own products and sells them directly to patients or institutions. The company's products include Eleview, used in endoscopy to improve visibility of the gastrointestinal mucosa. Cosmo Pharmaceuticals is an innovative company focused on the development of drugs that can help improve patients' lives. The company collaborates closely with other companies and research institutions to leverage the latest technologies and developments in the industry. With its broad portfolio of products in the field of gastroenterology, oncology, and infectious diseases, the company has a strong presence in the industry and actively advocates for more people to have access to the best medical treatments. Cosmo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Cosmo Pharmaceuticals's Return on Equity (ROE)

Cosmo Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Cosmo Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Cosmo Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Cosmo Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Cosmo Pharmaceuticals stock

What is the ROE (Return on Equity) of Cosmo Pharmaceuticals this year?

The ROE of Cosmo Pharmaceuticals this year is 0 undefined.

How has the Return on Equity (ROE) of Cosmo Pharmaceuticals developed compared to the previous year?

The ROE of Cosmo Pharmaceuticals has increased by -100% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Cosmo Pharmaceuticals?

A high ROE indicates that Cosmo Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Cosmo Pharmaceuticals?

A low ROE can indicate that Cosmo Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Cosmo Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Cosmo Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Cosmo Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Cosmo Pharmaceuticals?

Some factors that can influence Cosmo Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Cosmo Pharmaceuticals pay?

Over the past 12 months, Cosmo Pharmaceuticals paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 1.29 %. For the coming 12 months, Cosmo Pharmaceuticals is expected to pay a dividend of 1.05 EUR.

What is the dividend yield of Cosmo Pharmaceuticals?

The current dividend yield of Cosmo Pharmaceuticals is 1.29 %.

When does Cosmo Pharmaceuticals pay dividends?

Cosmo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, June, June, August.

How secure is the dividend of Cosmo Pharmaceuticals?

Cosmo Pharmaceuticals paid dividends every year for the past 8 years.

What is the dividend of Cosmo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 1.05 EUR are expected. This corresponds to a dividend yield of 1.3 %.

In which sector is Cosmo Pharmaceuticals located?

Cosmo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cosmo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cosmo Pharmaceuticals from 7/12/2024 amounting to 2 EUR, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.

When did Cosmo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Cosmo Pharmaceuticals in the year 2023?

In the year 2023, Cosmo Pharmaceuticals distributed 0.95 EUR as dividends.

In which currency does Cosmo Pharmaceuticals pay out the dividend?

The dividends of Cosmo Pharmaceuticals are distributed in EUR.